bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 4 from Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma
Authors: Ebelt Nancy D. , Zuniga Edith , Passi Kevin B. , Sobocinski Lukas J. , Manuel Edwin R.
Published: April 2023

Supplementary Figure 4 shows that treatment with X8768-BHs does not degrade HA is non-tumor tissues, and does not affaect total cellular content of tumor tissue where HA was degraded.
Supplementary Figure 3 from Hyaluronidase-Expressing Salmonella Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma
Authors: Ebelt Nancy D. , Zuniga Edith , Passi Kevin B. , Sobocinski Lukas J. , Manuel Edwin R.
Published: April 2023

Supplementary Figure 3 describes the ability of X8768 expressing bacterial luciferase to colonize tumors and peripheral tissues, as well as how HA degradation affects vasculature in PANC-1 tumors.
All supplemental figures tables and legends from The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria
Authors: Schultz Christopher W. , McCarthy Grace A. , Nerwal Teena , Nevler Avinoam , DuHadaway James B. , McCoy Matthew D. , Jiang Wei , Brown Samantha Z. , Goetz Austin , Jain Aditi , Calvert Valerie S. , Vishwakarma Vikalp , Wang Dezhen , Preet Ranjan , Cassel Joel , Summer Ross , Shaghaghi Hoora , Pommier Yves , Baechler Simone A. , Pishvaian Michael J. , Golan Talia , Yeo Charles J. , Petricoin Emanuel F. , Prendergast George C. , Salvino Joseph , Singh Pankaj K. , Dixon Dan A. , Brody Jonathan R.
Published: April 2023

All supplemental figures tables and legends
Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Authors: Cole Ryan N. , Chen Wei , Pascal Laura E. , Nelson Joel B. , Wipf Peter , Wang Zhou
Published: April 2023

Supplementary Data from (+)-JJ-74–138 is a Novel Noncompetitive Androgen Receptor Antagonist
Supplementary Data from The Monoacylglycerol Lipase Inhibitor JZL184 Inhibits Lung Cancer Cell Invasion and Metastasis via the CB1 Cannabinoid Receptor
Authors: Prüser Jan Lukas , Ramer Robert , Wittig Felix , Ivanov Igor , Merkord Jutta , Hinz Burkhard
Published: April 2023

Supplementary figures S1 - S6
Supplementary Data from ATR Inhibitor M6620 (VX-970) Enhances the Effect of Radiation in Non–Small Cell Lung Cancer Brain Metastasis Patient-Derived Xenografts
Authors: Baschnagel Andrew M. , Elnaggar Jacob H. , VanBeek Haley J. , Kromke Ashley C. , Skiba Justin H. , Kaushik Saakshi , Abel Lindsey , Clark Paul A. , Longhurst Colin A. , Nickel Kwangok P. , Leal Ticiana A. , Zhao Shuang G. , Kimple Randall J.
Published: April 2023

Supplementary Data
Supplementary Table 6 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
Authors: Jo Hitomi , Yagishita Shigehiro , Hayashi Yoshiharu , Ryu Shoraku , Suzuki Mikiko , Kohsaka Shinji , Ueno Toshihide , Matsumoto Yuji , Horinouchi Hidehito , Ohe Yuichiro , Watanabe Shun-ichi , Motoi Noriko , Yatabe Yasushi , Mano Hiroyuki , Takahashi Kazuhisa , Hamada Akinobu
Published: April 2023

Supplementary Table 6
Region of interest analysis - detail
Supplementary Table 3 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
Authors: Jo Hitomi , Yagishita Shigehiro , Hayashi Yoshiharu , Ryu Shoraku , Suzuki Mikiko , Kohsaka Shinji , Ueno Toshihide , Matsumoto Yuji , Horinouchi Hidehito , Ohe Yuichiro , Watanabe Shun-ichi , Motoi Noriko , Yatabe Yasushi , Mano Hiroyuki , Takahashi Kazuhisa , Hamada Akinobu
Published: April 2023

Supplementary Table 3
(A) Establishment status by histological subtype(B) Establishment status by gene aberration.
Supplementary Figure from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
Authors: Ishi Yukitomo , Zhang Yongzhan , Zhang Ali , Sasaki Takahiro , Piunti Andrea , Suri Amreena , Watanabe Jun , Abe Kouki , He Xingyao , Katagi Hiroaki , Bhalla Pankaj , Natsumeda Manabu , Zou Lihua , Shilatifard Ali , Hashizume Rintaro
Published: April 2023

Supplementary Figure from Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors
Supplementary Figure 1 from Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations
Authors: Jo Hitomi , Yagishita Shigehiro , Hayashi Yoshiharu , Ryu Shoraku , Suzuki Mikiko , Kohsaka Shinji , Ueno Toshihide , Matsumoto Yuji , Horinouchi Hidehito , Ohe Yuichiro , Watanabe Shun-ichi , Motoi Noriko , Yatabe Yasushi , Mano Hiroyuki , Takahashi Kazuhisa , Hamada Akinobu
Published: April 2023

Supplementary Figure 1
The spectra and annotations of fragment ions from pure test drugs of afatinib, gefitinib, osimertinib, poziotinib, brigatinib, crizotinib, entrectinib, and lorlatinib are shown.
Supplementary Materials and Methods from Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance
Authors: Bahcall Magda , Paweletz Cloud P. , Kuang Yanan , Taus Luke J. , Sim Taebo , Kim Nam Doo , Dholakia Kshiti H. , Lau Christie J. , Gokhale Prafulla C. , Chopade Pratik R. , Hong Fangxin , Wei Zihan , Köhler Jens , Kirschmeier Paul T. , Guo Jiannan , Guo Sujuan , Wang Stephen , Jänne Pasi A.
Published: April 2023

Application of Bliss independence to test for synergy effect of TKI combination treatment in vivo
Supplementary Figure S4 from Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases
Authors: Fox Gregory C. , Su Xinming , Davis Jennifer L. , Xu Yalin , Kwakwa Kristin A. , Ross Michael H. , Fontana Francesca , Xiang Jingyu , Esser Alison K. , Cordell Elizabeth , Pagliai Kristen , Dang Ha X. , Sivapackiam Jothilingam , Stewart Sheila A. , Maher Christopher A. , Bakewell Suzanne J. , Fitzpatrick James A.J. , Sharma Vijay , Achilefu Samuel , Veis Deborah J. , Lanza Gregory M. , Weilbaecher Katherine N.
Published: April 2023

TEM quantitation of average area per mitochondrion and GO Biological Process GSEA in 4T1 cells.
Supplementary Figure S3 from Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases
Authors: Fox Gregory C. , Su Xinming , Davis Jennifer L. , Xu Yalin , Kwakwa Kristin A. , Ross Michael H. , Fontana Francesca , Xiang Jingyu , Esser Alison K. , Cordell Elizabeth , Pagliai Kristen , Dang Ha X. , Sivapackiam Jothilingam , Stewart Sheila A. , Maher Christopher A. , Bakewell Suzanne J. , Fitzpatrick James A.J. , Sharma Vijay , Achilefu Samuel , Veis Deborah J. , Lanza Gregory M. , Weilbaecher Katherine N.
Published: April 2023

Docetaxel viability of hβ3-rescued β3KO1-BO1 cells compared to PyMT-BO1 in BMSC co-culture.
Supplemental File 5 from EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1
Authors: Weadick Brenna , Nayak Debasis , Persaud Avinash K. , Hung Sau Wai , Raj Radhika , Campbell Moray J. , Chen Wei , Li Junan , Williams Terence M. , Govindarajan Rajgopal
Published: April 2023

Video 5. PANC-1 cells stably overexpressing EpCAM are shown in this animation of a 3D reconstruction of compiled z-stack images. ENT1 (red), EpCAM (green), DAPI (blue).
Supplementary Figure from A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors
Authors: Fernández-Rodríguez Juana , Creus-Bachiller Edgar , Zhang Xiaohu , Martínez-Iniesta Maria , Ortega-Bertran Sara , Guha Rajarshi , Thomas Craig J. , Wallace Margaret R. , Romagosa Cleofe , Salazar-Huayna Lourdes , Reilly Karlyne M. , Blakely Jaishri O. , Serra-Musach Jordi , Pujana Miguel Angel , Serra Eduard , Villanueva Alberto , Ferrer Marc , Lázaro Conxi
Published: April 2023

Supplementary Figure from A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors
Figure S6 from 3D Collagen Vascular Tumor-on-a-Chip Mimetics for Dynamic Combinatorial Drug Screening
Authors: Wan Li , Yin Jun , Skoko John , Schwartz Russell , Zhang Mei , LeDuc Philip R. , Neumann Carola A.
Published: April 2023

Drug diffusion profiles for doxorubicin and cyclophosphamide
Supplementary Data from Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas
Authors: Zhang Hui , Bi Yongyan , Wei Yuxi , Liu Jiayang , Kuerban Kudelaidi , Ye Li
Published: April 2023

Supplementary data file including supplementary figure 1-4 and supplementary table 1-4.
Supplementary Figure S4 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

Treatment with Z-VAD-FMK did not suppress the combination growth inhibition effect of obinutuzumab plus prednisolone in resistant clones.
Supplementary Figure S3 from Obinutuzumab in Combination with Chemotherapy Enhances Direct Cell Death in CD20-Positive Obinutuzumab-resistant Non-Hodgkin Lymphoma Cells
Authors: Fujimura Takaaki , Yamashita-Kashima Yoriko , Kawasaki Natsumi , Yoshiura Shigeki , Harada Naoki , Yoshimura Yasushi
Published: April 2023

The effects of obinutuzumab or chemotherapeutic agents in parental SU-DHL-4 cells.
Supplementary Figures S1-S3 & Supplementary S1-S3 Legends from Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Authors: Lindemann Antje , Patel Ameeta A. , Tang Lin , Tanaka Noriaki , Gleber-Netto Frederico O. , Bartels Mason D. , Wang Li , McGrail Daniel J. , Lin Shiaw-Yih , Frank Steven J. , Frederick Mitchell J. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Single agent activity of B02 in HNSCC cell lines, Cell growth assay in HNSCC cells, Cell growth assay in HNSCC cells, and Synergy between B02 and AZD1775 is mediated in part through forced activation of CDK1 and inhibition of Chk1 associated with impaired Rad51-mediated homologous recombination repair in HNSCC cells.
Supplementary Figure S6 & Supplementary S6 Legend from Combined Inhibition of Rad51 and Wee1 Enhances Cell Killing in HNSCC Through Induction of Apoptosis Associated With Excessive DNA Damage and Replication Stress
Authors: Lindemann Antje , Patel Ameeta A. , Tang Lin , Tanaka Noriaki , Gleber-Netto Frederico O. , Bartels Mason D. , Wang Li , McGrail Daniel J. , Lin Shiaw-Yih , Frank Steven J. , Frederick Mitchell J. , Myers Jeffrey N. , Osman Abdullah A.
Published: April 2023

Tumor volume growth curves for individual mice in each treatment arm.
Supplementary Figure S6 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19
Authors: Tokunaga Yoshihiro , Sasaki Takahiro , Goto Shunsuke , Adachi Keishi , Sakoda Yukimi , Tamada Koji
Published: April 2023

Supplementary Figure S6 shows an expression of human CD20 on hCD20-P815 tumor cells.
Supplementary Figure S5 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19
Authors: Tokunaga Yoshihiro , Sasaki Takahiro , Goto Shunsuke , Adachi Keishi , Sakoda Yukimi , Tamada Koji
Published: April 2023

Supplementary Figure S5 shows the generation of long-term anti-tumor memory responses in vivo by 7Ã-19 P1A-T cell therapy.
Supplementary Figure S4 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19
Authors: Tokunaga Yoshihiro , Sasaki Takahiro , Goto Shunsuke , Adachi Keishi , Sakoda Yukimi , Tamada Koji
Published: April 2023

Supplementary Figure S4 shows the effects of anti-PD-1 mAb combination on the generation of memory T cell responses.
Supplementary Figure S2 from Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19
Authors: Tokunaga Yoshihiro , Sasaki Takahiro , Goto Shunsuke , Adachi Keishi , Sakoda Yukimi , Tamada Koji
Published: April 2023

Supplementary Figure S2 shows a diminished PD-1 expression on Pdcd1 gene-knockdown 7Ã-19 P1A-T cells.
Supplementary Data from Calicheamicin Antibody–Drug Conjugates with Improved Properties
Authors: Vollmar Breanna S. , Frantz Chris , Schutten Melissa M. , Zhong Fiona , del Rosario Geoffrey , Go Mary Ann T. , Yu Shang-Fan , Leipold Douglas D. , Kamath Amrita V. , Ng Carl , Xu Keyang , dela Cruz-Chuh Josefa , Kozak Katherine R. , Chen Jinhua , Xu Zijin , Wai John , Adhikari Pragya , Erickson Hans K. , Dragovich Peter S. , Polson Andrew G. , Pillow Thomas H.
Published: April 2023

Supplementary Data
Supplementary Figures & Legends from Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer
Authors: Dosch Austin R. , Singh Samara , Dai Xizi , Mehra Siddharth , Silva Iago De Castro , Bianchi Anna , Srinivasan Supriya , Gao Zhen , Ban Yuguang , Chen Xi , Banerjee Sulagna , Nagathihalli Nagaraj S. , Datta Jashodeep , Merchant Nipun B.
Published: April 2023

Supplementary Fig. S1-S4 and figure legends.
Supplementary Fig S4 from Heme Sequestration as an Effective Strategy for the Suppression of Tumor Growth and Progression
Authors: Wang Tianyuan , Ashrafi Adnin , Konduri Purna Chaitanya , Ghosh Poorva , Dey Sanchareeka , Modareszadeh Parsa , Salamat Narges , Alemi Parinaz Sadat , Berisha Eranda , Zhang Li
Published: April 2023

Figure S4. The effects of HeSPs on key markers of proliferation, apoptosis, and cellular bioenergetics in NSCLC tumor xenografts. A, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of the proliferation marker Ki67 in control and HeSP-treated tumors. B, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of the apoptosis marker cleaved caspase-3 (CASP3) in control and HeSP-treated tumors. C, Representative 40X IHC images of H1299 NSCLC tumor tissue sections showing the nuclear localization of MKI67. Scale bar, 20 Âµm. D, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of COX5A in control and HeSP-treated tumors. E, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of UQCRC2 in control and HeSP-treated tumors. F, Representative montage and 10X IHC images of H1299 NSCLC tumor tissue sections and graphs showing the levels of ATP5A in control and HeSP-treated tumors. Shown are montages, 10X, or 40X images of control and HeSP-treated tumor tissue sections stained with DAPI (row 1) or antibodies against the indicated protein (row 2) or merged images of DAPI and the indicated protein (row 3). The white rectangles in DAPI images denote the regions shown in 10X images. Scale bar, montage, 1 mm; 10X, 200 Î¼m. Protein levels were quantified, and data were plotted as mean {plus minus} SEM. *, P <Â€‰0.05; **, P < 0.01; ***, P < 0.005.
Supplementary Data from Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers
Authors: Salem Ahmed Hamed , Tao Zhi-Fu , Bueno Orlando F. , Chen Jie , Chen Shuang , Edalji Rohinton , Elmore Steven W. , Fournier Keith M. , Harper Kaid C. , Hong Richard , Jenkins Gary J. , Ji Jianguo , Judge Russell A. , Kalvass John C. , Klix Russell C. , Ku Yi-Yin , Leverson Joel D. , Marks Richard A. , Marsh Kennan C. , Menon Rajeev M. , Park Chang H. , Phillips Darren C. , Pu Yu-Ming , Rosenberg Saul H. , Sanzgiri Yeshwant D. , Sheikh Ahmad Y. , Shi Yi , Stolarik Deanne , Suleiman Ahmed A. , Wang Xilu , Zhang Geoff G.Z. , Catron Nathaniel D. , Souers Andrew J.
Published: April 2023

1. Measured pKa values of ABBV-167 (Table S1. Ionization constants of ABBV-167) 2. Preparation of ABBV-167 on large scale (Scheme S1: Synopsis of GMP synthesis of ABBV-167) 3. Preparation of clinical ABBV-167 drug supply 4. Animal pharmacokinetics (Table S2. Single dose pharmacokinetics of prodrug 3 and parent venetoclax in mouse and dog after IV dosing of prodrug 3. Table S3. Single dose pharmacokinetics of 3 after oral dosing in mouse and dog. Table S4. Single dose pharmacokinetics of parent venetoclax in mouse and dog after oral dosing of 3.) 5. Clinical study (Study design, Pharmacokinetic and statistical analysis, Safety and tolerability assessments, Clinical pharmacokinetic results, Table S5. Effect of prodrug and food on venetoclax bioavailability, Safety results) 6. Crystallography methods (Protein preparation. BCL-2 ABBV-167 complex crystallization. X-ray structure determination. Table S6. Diffraction data collection and refinement statistics for BCL-2 in complex with ABBV-167 (PDB code 7LHB))
Supplementary Figure from Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
Authors: Javaid Sehrish , Schaefer Antje , Goodwin Craig M. , Nguyen Victoria V. , Massey Frances L. , Pierobon Mariaelena , Gambrell-Sanders Da'Jhnae , Waters Andrew M. , Lambert Kathryn N. , Diehl J. Nathaniel , Hobbs G. Aaron , Wood Kris C. , Petricoin Emanuel F. , Der Channing J. , Cox Adrienne D.
Published: April 2023

Supplementary Figure from Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
Supplementary Data from Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
Authors: Javaid Sehrish , Schaefer Antje , Goodwin Craig M. , Nguyen Victoria V. , Massey Frances L. , Pierobon Mariaelena , Gambrell-Sanders Da'Jhnae , Waters Andrew M. , Lambert Kathryn N. , Diehl J. Nathaniel , Hobbs G. Aaron , Wood Kris C. , Petricoin Emanuel F. , Der Channing J. , Cox Adrienne D.
Published: April 2023

Supplementary Data from Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma
Supplementary Figure 5 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Tolerability of combination therapy. MDA-MB-453 cells were injected into the mammary fat pads of cycling female nu/nu mice; n=6-7 mice per group. Sevi and/or Abem were administered daily. Mouse weights were measured throughout the experiment. Mean {plus minus} standard error of the mean.
Supplementary Figure 4 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Overlap between RNAseq datasets from MDA-MB-453 ARHigh cells and HCI-009 PDX mice treated with Sevi. scRNAseq was performed on untreated MDA-MB-453 cells cultured in full serum media. Cells were divided in groups based on their expression of AR, ARLow and ARHigh. RNAseq was performed on HCI-009 PDX tumor from mice treated daily with vehicle or 150mg/kg/day Sevi. (A) Venn diagram of overlap between gene signatures. (B) Biological pathways identified by examining the list of 208 genes that overlap between datasets. Numbers per pathway represent the number of genes associated with each pathway.
Supplementary Figure 3 from Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer
Authors: Christenson Jessica L. , O'Neill Kathleen I. , Williams Michelle M. , Spoelstra Nicole S. , Jones Kenneth L. , Trahan G. Devon , Reese Jordan , Van Patten Elaina T. , Elias Anthony , Eisner Joel R. , Richer Jennifer K.
Published: April 2023

Single-cell RNAseq of AR expressing MDA-MB-453 TNBC cells. scRNAseq was performed on untreated MDA-MB-453 cells cultured in full serum media. Cells were divided in groups based on their expression of AR, ARLow and ARHigh. (A) tSNE plot of AR levels in cells clustered by gene expression. (B) IPA was performed on the genes differentially expressed between ARLow and ARHigh groups. Shown are the top 50 most significantly altered disease and function pathways and canonical pathways.
Supplementary Materials and Methods and Supplementary Tables 1-2 from Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition
Authors: Carnevalli Larissa S. , Taylor Molly A. , King Matthew , Coenen-Stass Anna M.L. , Hughes Adina M. , Bell Sigourney , Proia Theresa A. , Wang Yanjun , Ramos-Montoya Antonio , Wali Neha , Carroll Danielle , Singh Maneesh , Moschetta Michele , Gutierrez Pablo Morentin , Gardelli Cristina , Critchlow Susan E. , Klinowska Teresa , Fawell Stephen E. , Barry Simon T.
Published: April 2023

Supplementary Materials and Methods. Suplementary Table 1. Tumor Immuno-phenotyping. Suplementary Table 2. Flow cytometry panels.
Supplementary Table 2 from Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-l-glutamic Acid–coated Layer-by-Layer Nanoparticles
Authors: Tošić Isidora , Heppler Lisa N. , Egusquiaguirre Susana P. , Boehnke Natalie , Correa Santiago , Costa Daniel F. , Moore Elizabeth A. Grossman , Pal Sharmistha , Richardson Douglas S. , Ivanov Alexander R. , Haas-Kogan Daphne A. , Nomura Daniel K. , Hammond Paula T. , Frank David A.
Published: April 2023

Supplementary Table 2
Table S4 from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Associations between LIN28B rs314277/rs314276 and clinical outcomes in RAS wild type patients
Table S1 from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Characteristics of selected SNPs in RBP encoding genes
Supplementary Methods from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Details about the imputation
Figure S2 from RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC
Authors: Arai Hiroyuki , Cao Shu , Battaglin Francesca , Wang Jingyuan , Kawanishi Natsuko , Tokunaga Ryuma , Loupakis Fotios , Stintzing Sebastian , Soni Shivani , Zhang Wu , Mancao Christoph , Salhia Bodour , Mumenthaler Shannon M. , Cremolini Chiara , Heinemann Volker , Falcone Alfredo , Millstein Joshua , Lenz Heinz-Josef
Published: April 2023

Associations between selected SNPs and gene expression status in colon tissue from GTEx analysis
Figures S1-S7 Tables S1,S2 from Enhancing Proteotoxic Stress in Leiomyosarcoma Cells Triggers Mitochondrial Dysfunctions, Cell Death, and Antitumor Activity in vivo
Authors: Iuliano Luca , Drioli Sara , Pignochino Ymera , Cafiero Claudia Maria , Minisini Martina , D'Este Francesca , Picco Raffaella , Dalla Emiliano , Giordano Giorgia , Grignani Giovanni , Di Giorgio Eros , Benedetti Fabio , Felluga Fulvia , Brancolini Claudio
Published: April 2023

Supplementary Figure S1: Analysis of the mutational burden in sarcoma patients.Supplementary Figure S2: Characterization of 2c-induced cell death in LMS cells. Supplementary Figure S3: Dose dependent studies. Supplementary Figure S4: Sub-mitochondrial localization of the ATP-synthase-β subunit, Cytochrome c and DIABLO/SMAC. Supplementary Figure S5: STED super-resolution microscopy of mitochondria under 2c-induced proteotoxic stress. Supplementary Figure S6: Sub-mitochondrial localization of the ATP-synthase-β subunit, Cytochrome c and DIABLO/SMAC in LMS cells. Supplementary Figure S7: HSF1 expression in LMS cells. Supplementary Table S1: List of genes constituting the two 2c-signatures used in this study. Supplementary Table S2:The 2c proteotoxic stress signature
Table S5 from Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody–Drug Conjugates in Pancreatic Cancer
Authors: Tsujii Shigehiro , Serada Satoshi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Nomura Taisei , Murakami Ichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Supplementary Table S5
Table S1 from Glypican-1 Is a Novel Target for Stroma and Tumor Cell Dual-Targeting Antibody–Drug Conjugates in Pancreatic Cancer
Authors: Tsujii Shigehiro , Serada Satoshi , Fujimoto Minoru , Uemura Sunao , Namikawa Tsutomu , Nomura Taisei , Murakami Ichiro , Hanazaki Kazuhiro , Naka Tetsuji
Published: April 2023

Supplementary Table S1
Figure S5 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure S5. Genes identified by RNAseq are validated by qRT-PCR in enzalutamide-resistant and -sensitive cell lines.
Figure S2 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure S2. Overexpression of DNMT3B3 promotes an enzalutamide resistant phenotype in prostate cancer cells.
Figure S1 from Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer
Authors: Farah Elia , Zhang Zhuangzhuang , Utturkar Sagar M. , Liu Jinpeng , Ratliff Timothy L. , Liu Xiaoqi
Published: April 2023

Figure S1. The p53 and pRB pathways are involved in the enzalutamide-mediated increase of DNMT3B in prostate cancer cells.
Supplementary Fig S2 from IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer
Authors: Markov Spas Dimitrov , Caffrey Thomas C. , O'Connell Kelly A. , Grunkemeyer James A. , Shin Simon , Hanson Ryan , Patil Prathamesh P. , Shukla Surendra K. , Gonzalez Daisy , Crawford Ayrianne J. , Vance Krysten E. , Huang Ying , Eberle Kirsten C. , Radhakrishnan Prakash , Grandgenett Paul M. , Singh Pankaj K. , Madiyalakan Ragupathy , Daniels-Wells Tracy R. , Penichet Manuel L. , Nicodemus Christopher F. , Poole Jill A. , Jaffee Elizabeth M. , Hollingsworth Michael A. , Mehla Kamiya
Published: April 2023

Gating strategy for immune subsets in pancreatic tumor
Figures S1-S7 from The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
Authors: Briere David M. , Li Shuai , Calinisan Andrew , Sudhakar Niranjan , Aranda Ruth , Hargis Lauren , Peng David H. , Deng Jiehui , Engstrom Lars D. , Hallin Jill , Gatto Sole , Fernandez-Banet Julio , Pavlicek Adam , Wong Kwok-Kin , Christensen James G. , Olson Peter
Published: April 2023

Figures S1-S7
Supplementary Figure from Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
Authors: Ertveldt Thomas , De Beck Lien , De Ridder Kirsten , Locy Hanne , de Mey Wout , Goyvaerts Cleo , Lecocq Quentin , Ceuppens Hannelore , De Vlaeminck Yannick , Awad Robin Maximilian , Keyaerts Marleen , Devoogdt Nick , D'Huyvetter Matthias , Breckpot Karine , Krasniqi Ahmet
Published: April 2023

Supplementary Figure from Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177–Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model
Supplementary Data from High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells
Authors: Vernooij Lindy , Bate-Eya Laurel T. , Alles Lindy K. , Lee Jasmine Y. , Koopmans Bianca , Jonus Hunter C. , Schubert Nil A. , Schild Linda , Lelieveld Daphne , Egan David A. , Kerstjens Mark , Stam Ronald W. , Koster Jan , Goldsmith Kelly C. , Molenaar Jan J. , Dolman M. Emmy M.
Published: April 2023

Supplementary data including supplementary figures S1 to S6 and supplementary tables S1 to S3.
Supplementary Figure Legend from Association of Homologous Recombination–DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers
Authors: Cerniglia Michael , Xiu Joanne , Grothey Axel , Pishvaian Michael J. , Baca Yasmine , Hwang Jimmy J. , Marshall John L. , VanderWalde Ari M. , Shields Anthony F. , Lenz Heinz-Josef , Korn W. Michael , Salem Mohamed , Philip Philip A. , Goldberg Richard M. , Zeng Jia , Kim Sunnie S.
Published: April 2023

Supplementary Figure Legend
Supplementary Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells
Authors: Guo Lichao , Zhang Wen , Xie Yanqi , Chen Xi , Olmstead Emma E. , Lian Mengqiang , Zhang Baochen , Zaytseva Yekaterina Y. , Evers B. Mark , Spielmann H. Peter , Liu Xifu , Watt David S. , Liu Chunming
Published: April 2023

Supplementary Data from Diaminobutoxy-substituted Isoflavonoid (DBI-1) Enhances the Therapeutic Efficacy of GLUT1 Inhibitor BAY-876 by Modulating Metabolic Pathways in Colon Cancer Cells
Supplementary figures and legends from Suppression of Extracellular Vesicle VEGF-C–mediated Lymphangiogenesis and Pancreatic Cancer Early Dissemination By a Selective HDAC1/2 Inhibitor
Authors: Wang Chu-An , Li Chien-Feng , Huang Rho-Chi , Li Yo-Hua , Liou Jing-Ping , Tsai Shaw-Jenq
Published: April 2023

Supplementary data includes IC50 of SAHA and B390 (S1),bioinformatic analysis (S2 and S3), and tumor size (S4)
Figure S3 from Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
Authors: Wang Yuhua , Pandey Ram Naresh , Roychoudhury Kaushik , Milewski David , Kalin Tanya V. , Szabo Sara , Pressey Joseph G. , Hegde Rashmi S.
Published: April 2023

Figure S3 documents how loss of Eya3 or BZ treatment affects multicellular tumor spheroids generated with A673 and RD-ES cells.
Figure S2 from Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
Authors: Wang Yuhua , Pandey Ram Naresh , Roychoudhury Kaushik , Milewski David , Kalin Tanya V. , Szabo Sara , Pressey Joseph G. , Hegde Rashmi S.
Published: April 2023

Figure S2 documents the effects of loss of Eya3 in additional Ewing sarcoma cell lines and with additional clones.
Figure S1 from Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis
Authors: Wang Yuhua , Pandey Ram Naresh , Roychoudhury Kaushik , Milewski David , Kalin Tanya V. , Szabo Sara , Pressey Joseph G. , Hegde Rashmi S.
Published: April 2023

Figure S1 shows EYA3 expression levels in Ewing sarcoma cells, the effect of loss of Eya3 on cell migration and proliferation, and the effect of BZ on a tumor xenograft generated with A673 cells lacking EYA3.
Supplementary Data from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Authors: Grinkevitch Vera , Wappett Mark , Crawford Nyree , Price Stacey , Lees Andrea , McCann Christopher , McAllister Katherine , Prehn Jochen , Young Jamie , Bateson Jess , Gallagher Lewis , Michaut Magali , Iyer Vivek , Chatzipli Aikaterini , Barthorpe Syd , Ciznadija Daniel , Sloma Ido , Wesa Amy , Tice David A. , Wessels Lodewyk , Garnett Mathew , Longley Daniel B. , McDermott Ultan , McDade Simon S.
Published: April 2023

Supplementary Data from Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists
Supplementary information from Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells
Authors: Ishibashi Mariko , Yamamoto Junichi , Ito Takumi , Handa Hiroshi , Sunakawa-Kii Mika , Inokuchi Koiti , Morita Rimpei , Tamura Hideto
Published: April 2023

Supplementary Materials and methods; Supplementary Table S1: Cell characteristics and phenotypes of MM cell lines; Supplementary Table S2: Characteristics of patients with newly diagnosed MM in Figure 1H; Supplementary Table S3: Primer and shRNA sequence; Supplementary Table S4: Four hundred four genes differentially expressed in MM cell lines treated with or without POM; Supplementary Figure S1: Antitumor effect of LEN and POM on MM cell lines; Supplementary Figure S2: Relationship of POM sensitivity with CRBN expression; Supplementary Figure S3: DNA copy numbers of PD-L1 in MM cell lines; Supplementary Figure S4: The level of cell-surface expression of PD-L2; Supplementary Figure S5: Cell-surface expression of BCMA and TACI on MM cell lines treated with IMiDs; Supplementary Figure S6: Enrichment plots for the gene sets of the MAPK/ERK pathway; Supplementary Figure S7: In vivo analysis using a murine xenograft model of human myeloma MM.1S cells inoculated into the flanks of NOG mice; Supplementary Figure S8: PD-L1 mRNA expression in CRBN-knockout and Ikaros- and Aiolos-knockdown cells after 3-day cultivation with LEN or POM; Supplementary Figure S9: Ikaros binding sites in the promoter of the PD-L1 gene; Supplementary Figure S10: Cell proliferation and T-cell activation of CD8+ T cells on day 4 when co-cultivation of T cells with untreated or LEN-pretreated U266 cells was treated with durvalumab and LEN; Supplementary Figure S11: APRIL protein and mRNA expression in CRBN-knockout and Ikaros- and Aiolos-knockdown MOSTI-1 cells after 3-day cultivation with LEN or POM.
Supplementary Figure 1 from Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma
Authors: Dalton Krista M. , Krytska Kateryna , Lochmann Timothy L. , Sano Renata , Casey Colleen , D'Aulerio Alessia , Khan Qasim A. , Crowther Giovanna Stein , Coon Colin , Cai Jinyang , Jacob Sheeba , Kurupi Richard , Hu Bin , Dozmorov Mikhail , Greninger Patricia , Souers Andrew J. , Benes Cyril H. , Mossé Yael P. , Faber Anthony C.
Published: April 2023

Supplemental Figure 1. NVP-CGM097 and venetoclax combination cell viability assays. Cell viability assays were performed for 16h treatment of NVP-CGM097, venetoclax, or combination at indicated concentrations, with bliss synergy scores in (A) MYCN-wild-type, p53-wild-type, (B) MYCN-amplified, p53-mutant, and (C) MYCN-wild-type, p53-mutant NB cell lines. Red indicates synergy, blue indicates antagonism. (D) Plot of Bliss sum of cell lines in A-C along with cell lines in Fig. 1B, calculated by the summation of the bliss synergy scores across the doses presented.
Figure S5 from Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival
Authors: Goka Erik T. , Mesa Lopez Dayrelis T. , Lippman Marc E.
Published: April 2023

Supplementary Figure 5. (A) PSA RT-PCR on LNCaP cells treated stimulated with DHT in the presence of Biclutamide (Bic), Enzalutamide (Enz) or GYS32661 (661). (B) Androgen Response Element (ARE) luciferase assay on LNCaP cells stimulated with 10 nM DHT in the presence of Biclutamide (Bic), Enzalutamide (Enz) or GYS32661 (32661). (C) Androgen Response Element (ARE) luciferase assay on VCap cells transfected with siNSC or siRac1 and stimulated with 10 nM DHT. (D) Western blot analysis of LNCaP cells stimulated with 10 nM DHT in the presence of Enzalutamide or GYS32661. (E) Western blot analysis of siNSC and siRac1 LNCaP cells stimulated with 10 nM DHT.
Supplementary Table S3 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Protein kinases phosphosites
Supplementary Table S2 from Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma
Authors: Rossman Paul , Zabka Tanja S. , Ruple Audrey , Tuerck Dietrich , Ramos-Vara José A. , Liu Liling , Mohallem Rodrigo , Merchant Mark , Franco Jackeline , Fulkerson Christopher M. , Bhide Ketaki P. , Breen Matthew , Aryal Uma K. , Murray Elaine , Dybdal Noel , Utturkar Sagar M. , Fourez Lindsey M. , Enstrom Alexander W. , Dhawan Deepika , Knapp Deborah W.
Published: April 2023

Summary of findings from Figs. 3 and 5 and examples of genes involved.
Supplementary Table S3 from Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STS 1001 Randomized Phase III Trial
Authors: Martin-Broto Javier , Lopez-Alvarez Maria , Moura David S. , Ramos Rafael , Collini Paola , Romagosa Cleofe , Bagué Silvia , Renne Salvatore L. , Barisella Marta , Velasco Valerie , Coindre Jean-Michel , Lopez-Lopez Daniel , Dopazo Joaquin , Gambarotti Marco , Braglia Luca , Merlo Domenico Franco , Palmerini Emanuela , Stacchiotti Silvia , Quagliuolo Vittorio L. , Lopez-Pousa Antonio , Grignani Giovanni , Blay Jean-Yves , Brunello Antonella , Gutierrez Antonio , Valverde Claudia , Hindi Nadia , Dei Tos Angelo Paolo , Picci Piero , Casali Paolo G. , Gronchi Alessandro
Published: April 2023

Supplementary Table S3 - Multivariate analysis
Supplementary Data 8 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Authors: Branch Jonathan R. , Bush Tammy L. , Pande Vineet , Connolly Peter J. , Zhang Zhuming , Hickson Ian , Ondrus Janine , Jaensch Steffen , Bischoff James R. , Habineza Georges , Van Hecke Geert , Meerpoel Lieven , Packman Kathryn , Parrett Christopher J. , Chong Yolanda T. , Gottardis Marco M. , Bignan Gilles
Published: April 2023

JNJ-63576253 inhibits AR nuclear localization
Supplementary Figures and Tables from Functional Characterization of Brain Tumor-Initiating Cells and Establishment of GBM Preclinical Models that Incorporate Heterogeneity, Therapy, and Sex Differences
Authors: Garcia Cesar A. , Bhargav Adip G. , Brooks Mieu , Suárez-Meade Paola , Mondal Sujan K. , Zarco Natanael , ReFaey Karim , Jentoft Mark , Middlebrooks Erik H. , Snuderl Matija , Carrano Anna , Guerrero-Cazares Hugo , Schiapparelli Paula , Sarabia-Estrada Rachel , Quiñones-Hinojosa Alfredo
Published: April 2023

Supplementary Figures and Tables
Supplementary Data 5 from Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer
Authors: Branch Jonathan R. , Bush Tammy L. , Pande Vineet , Connolly Peter J. , Zhang Zhuming , Hickson Ian , Ondrus Janine , Jaensch Steffen , Bischoff James R. , Habineza Georges , Van Hecke Geert , Meerpoel Lieven , Packman Kathryn , Parrett Christopher J. , Chong Yolanda T. , Gottardis Marco M. , Bignan Gilles
Published: April 2023

93-cell line proliferation assay was performed and data analyzed by OncoLead
Supplementary Data from Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models
Authors: Handley Katelyn F. , Rodriguez-Aguayo Cristian , Ma Shaolin , Stur Elaine , Joseph Robiya , Bayraktar Emine , Dasari Santosh K. , Nguyen Nghi , Powell Reid T. , Sobieski Mary , Ivan Cristina , Kim Mark , Umamaheswaran Sujanitha , Glassman Deanna , Wen Yunfei , Amero Paola , Stephan Clifford , Coleman Robert L. , Landesman Yosef , Westin Shannon N. , Ram Prahlad T. , Sood Anil K.
Published: April 2023

Revised Supplementary Data Demonstrating All Supplementary Figures 1-6 and Supplementary Table 1
Supplementary Data from SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors
Authors: Gonzalez-Junca Alba , Liu Frances D. , Nagaraja Archana S. , Mullenix Alyssa , Lee Chen-Ting , Gordley Russell M. , Frimannsson Daniel O. , Maller Ori , Garrison Brian S. , Iyer Dharini , Benabbas Anissa , Truong Tiffany A. , Quach Allison , Tian Mengxi , Martinez Rowena , Savur Rishi , Perry-McNamara Alyssa , Nguyen Denny , Almudhfar Niran , Blanco Carmina , Huynh Christina , Nand Asish , Lay Yu-An E. , Magal Ashita , Mangalampalli Sravani , Lee Philip J. , Lu Timothy K. , Lee Gary
Published: April 2023

Supplementary Figure1 shows MSC homing to tumor and other organs in vivo using a bioluminescent reporter. Supplementary Figure 2. Characterization of tumor immune infiltrate of syngeneic preclinical intraperitoneal tumor models CT26-ip and B16F10-ip using IHC and flow cytometry. Supplementary Figure 3. Kaplan Meier Survival in B16F10-ip model comparing multiple combinations of effector cytokines expressed by MSCs. Supplementary Figure 4. Shows data supporting the construct optimization for SENTI-101 including promoter, orientation and signal sequence changes. Supplementary Figure 5. IL-21 functional validation using UO2S IL-21 receptor dimerization reporter assay. Supplementary Table 1. Shows the DNA sequence of SB00880, the lentiviral construct used to engineer SENTI-101. Supplementary Figure 6. Shows the SENTI-101 manufacturing process overview. Supplementary Figure 7. Shows supporting data for the study of pharmacokinetics and pharmacodynamics of SENTI-101. Supplementary Figure 8. Shows individual tumor burden for each mouse measured by bioluminescence imaging (BLI) after treatment with SENTI-101 or controls. Supplementary Figure 9. Percent change in mouse body weight after treatment. Supplementary Figure 10. Shows the controls and supporting data for the selective depletion of immune cell types. Supplementary Figure 11. Characterization of tumor infiltrating lymphocytes (TILs) in the B16F10-ip tumor model after treatment with mSENTI-101. Supplementary Figure 12. Anti-tumor immune response induced by SENTI-101 in CT-26ip model. Supplementary Figure 13. Shows individual tumor burden for each mouse measured by BLI after treatment with SENTI-101 and in combination with checkpoint inhibitor anti-PD-1.
Supplementary Data 2 from Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer
Authors: Khawaja Hajrah , Briggs Rebecca , Latimer Cheryl H. , Rassel Mustasin , Griffin Daryl , Hanson Lyndsey , Bardelli Alberto , Di Nicolantonio Frederica , McDade Simon S. , Scott Christopher J. , Lambe Shauna , Maurya Manisha , Lindner Andreas U. , Prehn Jochen H.M. , Sousa Jose , Winnington Chris , LaBonte Melissa J. , Ross Sarah , Van Schaeybroeck Sandra
Published: April 2023

concentrations of drugs
Supplementary Data 1 from Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer
Authors: Khawaja Hajrah , Briggs Rebecca , Latimer Cheryl H. , Rassel Mustasin , Griffin Daryl , Hanson Lyndsey , Bardelli Alberto , Di Nicolantonio Frederica , McDade Simon S. , Scott Christopher J. , Lambe Shauna , Maurya Manisha , Lindner Andreas U. , Prehn Jochen H.M. , Sousa Jose , Winnington Chris , LaBonte Melissa J. , Ross Sarah , Van Schaeybroeck Sandra
Published: April 2023

antibodies
Supplementary Figure from Lurbinectedin Inhibits the EWS–WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor
Authors: Gedminas Jenna M. , Kaufman Rebecca , Boguslawski Elissa A. , Gross Amy C. , Adams Marie , Beddows Ian , Kitchen-Goosen Susan M. , Roberts Ryan D. , Grohar Patrick J.
Published: April 2023

Supplementary Figure from Lurbinectedin Inhibits the EWS–WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor
Supplementary Table 1 from Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death
Authors: Jenkins Laura J. , Luk Ian Y. , Fairlie W. Douglas , Lee Erinna F. , Palmieri Michelle , Schoffer Kael L. , Tan Tao , Ng Irvin , Vukelic Natalia , Tran Sharon , Tse Janson W.T. , Nightingale Rebecca , Alam Zakia , Chionh Fiona , Iatropoulos George , Ernst Matthias , Afshar-Sterle Shoukat , Desai Jayesh , Gibbs Peter , Sieber Oliver M. , Dhillon Amardeep S. , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary table 1
Figure S3 from Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death
Authors: Jenkins Laura J. , Luk Ian Y. , Fairlie W. Douglas , Lee Erinna F. , Palmieri Michelle , Schoffer Kael L. , Tan Tao , Ng Irvin , Vukelic Natalia , Tran Sharon , Tse Janson W.T. , Nightingale Rebecca , Alam Zakia , Chionh Fiona , Iatropoulos George , Ernst Matthias , Afshar-Sterle Shoukat , Desai Jayesh , Gibbs Peter , Sieber Oliver M. , Dhillon Amardeep S. , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary figure 3 shows combining trametinib with different classes of HDAC inhibitors in COLO 201 cells
Figure S1 from Genotype-Tailored ERK/MAPK Pathway and HDAC Inhibition Rewires the Apoptotic Rheostat to Trigger Colorectal Cancer Cell Death
Authors: Jenkins Laura J. , Luk Ian Y. , Fairlie W. Douglas , Lee Erinna F. , Palmieri Michelle , Schoffer Kael L. , Tan Tao , Ng Irvin , Vukelic Natalia , Tran Sharon , Tse Janson W.T. , Nightingale Rebecca , Alam Zakia , Chionh Fiona , Iatropoulos George , Ernst Matthias , Afshar-Sterle Shoukat , Desai Jayesh , Gibbs Peter , Sieber Oliver M. , Dhillon Amardeep S. , Tebbutt Niall C. , Mariadason John M.
Published: April 2023

Supplementary Figure 1 shows the synergistic effect of trametinib plus panobinostat in CRC cell lines and PDTO's
Supplementary Methods and Tables from Inhibition of the MNK1/2–eIF4E Axis Augments Palbociclib-Mediated Antitumor Activity in Melanoma and Breast Cancer
Authors: Prabhu Sathyen A. , Moussa Omar , Gonçalves Christophe , LaPierre Judith H. , Chou Hsiang , Huang Fan , Richard Vincent R. , Ferruzo Pault Y. M. , Guettler Elizabeth M. , Soria-Bretones Isabel , Kirby Laura , Gagnon Natascha , Su Jie , Silvester Jennifer , Krisna Sai Sakktee , Rose April A. N. , Sheppard Karen E. , Cescon David W. , Mallette Frédérick A. , Zahedi Rene P. , Borchers Christoph H. , del Rincon Sonia V. , Miller Wilson H.
Published: April 2023

Supplementary methods and Tables 1, 2, 3, 4, and 6